Table 2.

Three-year outcomes of the study population, n (%)^‡

Variable	Dual therapy responders (n = 64)	Aspirin poor responders (n = 20)	Clopidogrel poor responders (n = 23)	Poor responders to dual therapy (n = 16)	p
Primary outcomes *	4 (6.3)	3 (15.0)	5 (21.7)	8 (50.0)	< 0.001
Secondary outcomes†
Cardiac mortality	0 (0)	1 (5.0)	0 (0)	3 (18.8)	0.002
Non-fatal MI	1 (1.6)	1 (5.0)	2 (8.7)	2 (12.5)	0.283
TVR	0 (0)	1 (5.0)	3 (13.0)	3 (18.8)	0.010
Stroke	0 (0)	0 (0)	0 (0)	0 (0)	---
Advanced heart failure	3 (4.7)	1 (5.0)	2 (8.7)	2 (12.5)	0.671

TVR: target vessel revascularization; MI: myocardial infarction; Asp: aspirin; Clop: Clopidogrel.

^*Primary clinical outcomes were composed of cardiovascular (CV) mortality, non-fatal reinfarction, target vessel revascularization(TVR), advanced heart failure, stroke.

^†Secondary clinical outcomes were CV mortality, non-fatal reinfarction, TVR, stroke, and advanced heart failure separately;

^‡all data in the table were compared byt the chi-square test and expressed as percentages.